Taste masked and rapidly disintegrating ultra thin iron orodispersible film and a process thereof The present disclosure generally relates to self administrable oral formulation of 5 iron. Specifically, the disclosure provides ultra thin orodispersible films (ODFs)—a novel patient centered innovation and excellent alternatives to traditional solid dosage forms—tablets and capsules. The instant disclosure provides iron containing ODFs that are taste masked and disintegrate rapidly when administered to tongue. They are easy to carry and will be used by subjects such as paediatrics, 10 geriatrics and pregnant women and many others to treat iron deficiency and its related disorders. These iron ODFs are a potential alternative, particularly, to subjects who depend a lot on iron supplements infused via parenteral route.

Proposed are a microcapsule having a core-shell structure that has high-temperature durability and solvent resistance and is environment-friendly. The microcapsule includes a core portion containing a hydrophobic active component and a shell portion surrounding the core portion and containing a silane crosslinkable polyurethane-based resin derived from a crosslinkable alkoxy silane group-terminated prepolymer.

The present invention refers to a pharmaceutical formulation for injection comprising fluorescent nanoparticles as in vivo diagnostics. The present invention relates to an injectable pharmaceutical formulation for human medicine and/or veterinary use, comprising 17% to 20% per weight of poloxamer 407 and 3%-15% per weight of poloxamer 188, 0.10 nM to 10.0 μM fluorescent nanoparticles and water or an aqueous buffer, wherein the pharmaceutical formulation is liquid at 4° C.-32° C. and forms a gel at about 37° C., their use as an in vivo marker and methods of their preparation. The inventive formulation is useful for local control and prevention of spreading/diffusion of nanoparticles, and thus allows full utilization of their quantum physics properties for example as a tool to enable surgical precision of tumor removal; even without tumor specific epitope binding antibodies.

The present invention relates to the field of coating pharmaceutical substrates. In particular, the invention relates to methods of coating of pharmaceutical substances, pharmaceutical ingredients or a blend of them. The invention also provides a method of making a pharmaceutical formulation which may be processed into a pharmaceutical dosage form, which utilizes solid pharmaceutical particles and a pharmaceutical formulation obtained by the method. The methods of the invention utilize atomic layer deposition technology. The novel methods allow difficult, moisture sensitive and electrically charged pharmaceutical substrates to be easily processable.

A microcapsule, in particular of spherical shape, having a hollow capsule core encased by a capsule shell, characterized in that the capsule shell is at least partially made of hydrated cementitious material. A method for the production of a microcapsule includes the steps of: a) preparing of a suspension of particulate cementitious material in a solvent b) preparing a dispersion by mixing the suspension of step a) with an immiscible fluid so that (i) the suspension is present as a dispersed phase in the fluid as a dispersion medium or that (ii) the fluid is present as the dispersed phase in the suspension as the dispersion medium, such that the particulate material of the suspension adsorbs at least partially at a phase boundary between the fluid and the suspension, and c) allowing the particulate material adsorbed at the phase boundary to hydrate with the formation of an individual microcapsule.

The present invention provides microcapsules encapsulating hydrophilic or hydrophobic active agents in an inorganic shell, processes for their preparation and compositions comprising them.

Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

A micro particle, suitable for use in pharmaceuticals, is comprised of a drug particle having a size within the range of 1-10 microns and a metallic coating overlying the drug particle. The metallic coating can modulate the release of the drug from the micro particle. The metallic coating can be applied by physical vapor deposition (PVD).

Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.

A composite particle including a core with at least one carrier material; a fluidizing material layer on the surface of the core; and an outer layer comprising nanoparticles of an ingestible material distributed in at least one matrix-forming material. A process of making the composite particles includes the steps of dry coating carrier particles with a fluidizing material; preparing a suspension of nanoparticles of an ingestible material distributed in a matrix-forming material; and fluid bed coating the carrier particles with the suspension. The process and products provide quick dissolving composite particles which can be used for delivery of poorly water soluble ingestible materials in suitable dosage forms. The process of the invention reduces or prevents particle agglomeration during fabrication of the composite particles to enable delivery and quick redispersion of nanoparticles of the ingestible material from a dosage form.